Product Description
Mechanisms of Action: mAChR Agonist,nAChR Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Belgium | Brazil | Canada | Chile | Colombia | Czech | Dominican Republic | Ecuador | France | Germany | Hong Kong | Hungary | Ireland | Korea | Lebanon | Luxembourg | Malaysia | Mexico | Netherlands | New Zealand | Pakistan | Peru | Philippines | Poland | Portugal | Russia | Singapore | Slovenia | Sweden | Switzerland | Taiwan | Thailand | Turkey | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|